Research and Clinical Trials

Brief Description  
The purpose of this resea4rch study is to evaluate the durability of the effectiveness and safety of a study drug called droxidopa (also known by the trade name NORTHERATM) in people with symptomatic Neurogenic Orthostatic Hypotension (NCH)
Who may be Eligible  
This is a double-blind placebo controlled, intervention study that can last up to 36 weeks. Eligible patients must be at least 18 years of age and have any of the diagnoses listed. Once enrolled, patient will be randomized "like flipping a coin" into 2 groups. Group 1 will receive droxidopa and Group 2 will receive placebo. This part of the study is double-blind which means that neither the study staff or study patients will know which group participants are in.
Start Date  
IRB Number  
Principal Investigator  
Iyer, Sanjay S.
Contact Name  

For More Information, Contact  Maryanne  , Burdette
Phone:  (704) 446-1925  Fax:  (704) 446-0840  
Address:Neurosciences Institute Neurology-Charlotte 1010 Edgehill Road North Charlotte, NC 28207